Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion

ACTA MEDICA INDONESIANA · Vol. 54 No. 4 (2023)

ISSN
2338-2732, 0125-9326
Terbit
2023-01-10
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Indonesia ranks seventh with the highest number of cases of type 2 diabetes mellitus (T2DM). T2DM is associated with major undesirable complications including cardiovascular disease and chronic kidney disease. Kidneys play a major role in maintaining glucose homeostasis, leading the development of sodium glucose transporter inhibitors (SGLT2i). These inhibitors block renal sodium and glucose reabsorption. Several cardiovascular trials proved that SGLT2i have cardioprotective and renoprotective roles and have been suggested as a drug of choice in primary and secondary prevention and management of cardiorenal complications associated with T2DM. This review highlights the need for a multidisciplinary recommendation for T2DM management in Indonesian population. Additionally, it is vital to provide the perspective of Indonesian medical experts in terms of screening, diagnosis and treatment as the outcome differs geographically. An expert panel of 6 members from Indonesia was convened to review the existing literature and develop an expert-based review/ summary on this topic. Members were chosen for their proficiency in diabetes, kidney disease and cardiovascular disease. The experts opined that the early use of SGLT2i will be effective in preventing and minimising the progression of cardiorenal complications. Moreover, a consistent multidimensional approach is necessary for improved outcomes.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 253 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Kuntjoro HarimurtiAfiliasi tidak diketahui5
Cleopas Martin RumendeAfiliasi tidak diketahui4
Evy YunihastutiAfiliasi tidak diketahui4
Eka GinanjarAfiliasi tidak diketahui4
Siti SetiatiAfiliasi tidak diketahui4
Idrus AlwiAfiliasi tidak diketahui4
Muhadi MuhadiAfiliasi tidak diketahui3
Andhika RachmanAfiliasi tidak diketahui3
Alvina WidhaniAfiliasi tidak diketahui3
Ika Prasetya WijayaAfiliasi tidak diketahui2
Hamzah ShatriAfiliasi tidak diketahui2
Juferdy KurniawanAfiliasi tidak diketahui2
Pringgodigdo NugrohoAfiliasi tidak diketahui2
Lugyanti SukrismanAfiliasi tidak diketahui2
Simon SalimAfiliasi tidak diketahui2
Nurul Inayah RahmaniAfiliasi tidak diketahui2
Ikhwan RinaldiAfiliasi tidak diketahui2
Adityo SusiloAfiliasi tidak diketahui2
Esthika DewiastyAfiliasi tidak diketahui2
Suzanna ImmanuelAfiliasi tidak diketahui2
Arif MansjoerAfiliasi tidak diketahui2
Iris RengganisAfiliasi tidak diketahui2
Dicky Levenus TahaparyAfiliasi tidak diketahui2
Anshari Saifuddin HasibuanAfiliasi tidak diketahui2
Sukamto KoesnoeAfiliasi tidak diketahui2
Suzy MariaAfiliasi tidak diketahui2
Andi Makbul AmanAfiliasi tidak diketahui2
Erwanto Budi WinulyoAfiliasi tidak diketahui2
Syahidatul WafaAfiliasi tidak diketahui2
Riadi WirawanAfiliasi tidak diketahui1
Ailinda Theodora TedjaAfiliasi tidak diketahui1
Fify HenrikaAfiliasi tidak diketahui1
Aulia RizkaAfiliasi tidak diketahui1
Mita Hafsah SaraswatiAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Early Recognition of Type 2 Diabetes Complications and Use of SGLT2i in Multidisciplinary Approach: Indonesian Perspective - An Expert Opinion</dc:title>
	<dc:creator>Lydia, Aida</dc:creator>
	<dc:creator>Suastika, Ketut</dc:creator>
	<dc:creator>Martosuwignjo, Pranawa</dc:creator>
	<dc:creator>Sibarani, Roy Panusunan</dc:creator>
	<dc:creator>Nasution, Sally Aman</dc:creator>
	<dc:creator>Sulistijo, Soebagijo Adi</dc:creator>
	<dc:subject xml:lang="en-US">Type 2 Diabetes Mellitus</dc:subject>
	<dc:subject xml:lang="en-US">SGLT2i</dc:subject>
	<dc:subject xml:lang="en-US">Cardiorenal complications</dc:subject>
	<dc:description xml:lang="en-US">Indonesia ranks seventh with the highest number of cases of type 2 diabetes mellitus (T2DM). T2DM is associated with major undesirable complications including cardiovascular disease and chronic kidney disease. Kidneys play a major role in maintaining glucose homeostasis, leading the development of sodium glucose transporter inhibitors (SGLT2i). These inhibitors block renal sodium and glucose reabsorption. Several cardiovascular trials proved that SGLT2i have cardioprotective and renoprotective roles and have been suggested  as a drug of choice in primary and secondary prevention and management of cardiorenal complications associated with T2DM. This review highlights the need for a multidisciplinary recommendation for T2DM management in Indonesian population. Additionally, it is vital to provide the perspective of Indonesian medical experts in terms of screening, diagnosis and treatment as the outcome differs geographically. An expert panel of 6 members from Indonesia was convened to review the existing literature and develop an expert-based review/ summary on this topic. Members were chosen for their proficiency in diabetes, kidney disease and cardiovascular disease. The experts opined that the early use of SGLT2i will be effective in preventing and minimising the progression of cardiorenal complications. Moreover, a consistent multidimensional approach is necessary for improved outcomes.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2023-01-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2143</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 54 No. 4 (2022): Acta Medica Indonesiana; 653</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2143/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2023 Aida Lydia, Ketut Suastika, Pranawa Martosuwignj, Roy Panusunan Sibarani, Sally Aman Nasution, Soebagijo Adi Sulistijo</dc:rights>
</oai_dc:dc>